Chlorpheniramine for motion sickness

Journal of Vestibular Research: Equilibrium and Orientation

Volumn 14, Issue 1, 2004, Pages 53-61

  Buckey, Jay C ^a,b   Alvarenga, Donna ^a   Cole, Bernard ^a   Rigas, James R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chlorpheniramine; Cutaneous administration; Motion sickness; Neuropsychological tests

Indexed keywords

CHLORPHENIRAMINE; LACTOSE;

ADULT; ALERTNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MOTION SICKNESS; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; ROTATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA;

NON-PROGRAMMATIC;

ADULT; ANTI-ALLERGIC AGENTS; AROUSAL; CHLORPHENIRAMINE; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOTION SICKNESS; ROTATION;

EID: 2442501233     PISSN: 09574271     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. K.S. Babe and W.E. Serafin, Histamine, bradykinin and their antagonists, in: Goodman and Gilman's The Pharmacologic Basis of Therapeutics, J.G. Hardman and L.E. Limbird, eds, 9th ed. New York: McGraw Hill, 1996, pp. 581-600.
2. J. Bergman, Psychomotor stimulant effects of the stereoisomers of chlorpheniramine, Psychopharmacology 100(1) (1990), 132-134.
3. O.L. Bock and C.M. Oman, Dynamics of subjective discomfort in motion sickness as measured with a magnitude estimation method. Aviation Space & Environmental Medicine 53(8) (1982), 773-777.
4. N.J. Brown and L.J. Roberts, Histamine, Bradykinin and their Antagonists, in: Goodman and Gilman's The Pharmacological Basis of Therapeutics, J.G. Hardman and L.E. Limbird, eds, 10th ed. New York,: McGraw-Hill, 2001, pp. 645-668.
5. A. Burkhalter, D.J. Julius and B.G. Katzung, Histamine, Serotonin and the Ergot Alkaloids, in: Basic and Clinical Pharmacology, B.G. Katzung, ed., 7th ed. Stamford, CT: Appleton and Lange, 1998, pp. 261-286.
6. H.I. Chinn, S. Handford, T.E. Cone and P.E. Smith, The effectiveness of various drugs for the prophylaxis of seasickness, American Journal of Medicine 12 (1952), 433-439.
7. H.I. Chinn, S.W. Handford, P.K. Smith, T.E. Cone, R.F. Redmond and J.V. Maloney, et al., Evaluation of some drugs in seasickness, Journal of Pharmacology and Experimental Therapeutics 108 (1953), 69-79.
8. D.F. Dinges, F. Pack, K. Williams, K.A. Gillen, J.W. Powell, G.E. Ott, C. Aptowicz and A.I. Pack, Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night, Sleep 20(4) (1997), 267-267.
9. A. Graybiel and E.F. Miller, The otolith organs as a primary etiological factor in motion sickness: with a note on off-vertical rotation. Fourth Symposium on the Role of the Vestibular Organs in the Space Environment, NASA SP-187 (1968), 53-64.
10. A. Graybiel and E.F. Miller, 2d., Off-vertical rotation: a convenient precise means of exposing the passive human subject to a rotating linear acceleration vector, Aerospace Medicine 41(4) (1970), 407-410.
11. M.E. Jewett, D.J. Dijk, R.E. Kronauer and D.F. Dinges, Dose-response relationship between sleep duration and human psychomotor vigilance and subjective alertness, Sleep 22(2) (1999), 171-179.
12. E.K. Kastrup, Drug Facts and Comparisons 2003, ed. St. Louis, MO: Walters and Kluwer; 2003.
13. G.W. Knox, D. Woodard, W. Chelen, R. Ferguson and L. Johnson, Phenytoin for motion sickness: clinical evaluation, Laryngoscope 104(8 Pt 1) (1994), 935-939.
14. R.L. Kohl, Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration, Aviation Space & Environmental Medicine 58(2) (1987), 125-131.
15. A. Labelle and R. Tislow, Studies on prophenpyridamine (Trimeton) and chlorprophenpyridamine (Chlortrimeton), Journal of Pharmacology and Experimental Therapeutics 113 (1955), 72-88.
16. J.B. Lucot, Pharmacology of motion sickness, Journal of Vestibular Research 8(1) (1998), 61-66.
17. E.F. Miller and A. Graybiel, Perception of the upright and susceptibility to motion sickness as functions of tilt angle and angular velocity in off-vertical rotation. Fifth Symposium on the Role of the Vestibular Organs in Space Exploration, NASA SP-314 (1970), 99-103.
18. E.F. Miller, 2d and Graybiel, A. A provocative test for grading susceptibility to motion sickness yielding a single numerical score, Acta Oto-Laryngologica 274 (1970), 1-20.
19. D.B. Mowrey and D.E. Clayson, Motion sickness, ginger, and psychophysics, Lancet 1(8273) (1982), 655-657.
20. D.F. Neri, D. Wiegmann, R.R. Stanny, S.A. Shappell, A. McCardie and D.L. McKay, The effects of tyrosine on cognitive performance during extended wakefulness, Aviation Space & Environmental Medicine 66(4) (1995), 313-319.
21. J.T. Reason and J.J. Brand, Motion Sickness. London: Academic Press; 1975.
22. G.S. Richardson, J.K. Wyatt, J.P. Sullivan, E.J. Orav, A.E. Ward, M.A. Wolf and C.A. Czeisler, Objective assessment of sleep and alertness in medical house staff and the impact of protected time for sleep. Sleep 19(9) (1996), 718-726.
23. E. Sakurai, S. Yamasaki, N. Hikichi and K. Onodera, Effects of d-, 1- and d1-chlorpheniramine on dopamine and 3,4-dihydroxyphenylacetic acid levels in the regional parts of rat brain, Tohoku Journal of Experimental Medicine 163(4) (1991), 239-244.
24. N. Sperber, D. Papa and E. Schwenk, Aryl-(2-pyridyl)-amino alkanes and their production, Schering Corporation (1951).
25. J.R. Stott, G.R. Barnes, R.J. Wright and C.J. Ruddock, The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. British Journal of Clinical Pharmacology 27(2) (1989), 147-157.
26. C.D. Wood, J.E. Manno, B.R. Manno, H.M. Redetzki, M. Wood and W.A. Vekovius, Side effects of antimotion sickness drugs, Aviation Space & Environmental Medicine 55(2) (1984), 113-116.
27. D. Woodard, G. Knox, K.J. Myers, W. Chelen and B. Ferguson, Phenytoin as a countermeasure for motion sickness in NASA maritime operations, Aviation Space & Environmental Medicine 64(5) (1993), 363-366.